Summary
[Olin Bio: Net profit of 111 million yuan in 2021, a year-on-year increase of 206.18%]Olin Bio released the 2021 annual performance report on the evening of February 22. The company will achieve a total operating income of 487 million yuan in 2021, a year-on-year increase of 52.23%; The net profit for the owner of the parent company was 111 million yuan, a year-on-year increase of 206.18%; the basic earnings per share was 0.29 yuan. (China Securities Journal)
Olin BioThe 2021 annual release will be released on the evening of February 22performanceExpress, the company will achieve a total operating income of 487 million yuan in 2021, a year-on-year increase of 52.23%;net profit111 million yuan, a year-on-year increase of 206.18%; basic earnings per share were 0.29 yuan.
For performance growth reasons,Olin BioSaid that the main reason is that in 2021, the company will continue to strengthen market development and channel construction, and the sales of adsorbed tetanus vaccine will continue to grow.Operating income。
Olin BioIt is a biopharmaceutical enterprise focusing on the research and development, production and sales of human vaccines. In 2021, the company’s group A group C meningococcal polysaccharide conjugate vaccine will be released and marketed for the first time.
(Article source: Chinasecuritiesnewspaper)
